Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

Status Completed

Clinical Trial Summary

The purpose of the present study is to explore the efficacy of small doses of oral glibenclamide on brain edema after acute primary intracerebral hemorrhage (ICH), and improving the prognosis of patients.

Clinical Trial Description

In order to explore the efficacy and safety of oral glibenclamide on brain edema after acute primary ICH, a web-based 1:1 randomization process will be employed to assign 220 subjects to Glibenclamide group (giving standard management for ICH plus glibenclamide) or Control group (giving standard management for ICH). The investigators will make a neurofunctional assessment at baseline, and 3 days, 7 days, 90 days after enrollment. The investigators also assess the midline shift, and the change in the volume of ICH and perihematomal edema (PHE) from the initial to follow-up (3 days and 7days after enrollment). The serious adverse events of all-cause mortality, cardiac-related and blood glucose-related adverse events will be collected to assess the safety of glibenclamide. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03741530
Study type	Interventional
Source	Xijing Hospital
Contact
Status	Completed
Phase	N/A
Start date	December 15, 2018
Completion date	September 23, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05089331` - ROSE-Longitudinal Assessment With Neuroimaging
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Active, not recruiting	`NCT04522102` - Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase	Phase 3
Terminated	`NCT04178746` - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting	`NCT03956485` - Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Enrolling by invitation	`NCT02920645` - Multicenter Validation of the AVICH Score	N/A
Recruiting	`NCT02625948` - Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign	Phase 2
Completed	`NCT02478177` - Addressing Real-world Anticoagulant Management Issues in Stroke
Completed	`NCT01971359` - Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study	N/A
Terminated	`NCT00990509` - Albumin for Intracerebral Hemorrhage Intervention	Phase 2
Completed	`NCT01261091` - Early Tracheostomy in Ventilated Stroke Patients	N/A
Completed	`NCT00716079` - The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial	N/A
Recruiting	`NCT00222625` - rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets	Phase 2
Recruiting	`NCT05095857` - The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury	Phase 4
Recruiting	`NCT04548596` - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Not yet recruiting	`NCT06429332` - International Care Bundle Evaluation in Cerebral Hemorrhage Research	Phase 4
Recruiting	`NCT05492474` - Cranial Ultrasound for Prehospital ICH Diagnosis	N/A
Not yet recruiting	`NCT05502874` - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting	`NCT04604587` - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA	Phase 3
Recruiting	`NCT05504941` - Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage	N/A

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage — GATE-ICH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms